Abstract Purpose of Review This review will discuss the challenges facing chimeric antigen
receptor (CAR)-T cell application for solid tumors and opportunities to overcome these …

Genetically engineered immune cells expressing chimeric antigen receptors (CARs) have
emerged as a new game changer in cancer immunotherapy. The utility of CAR T cell therapy …

Central nervous system (CNS) tumors are the most common solid malignancy in the
pediatric population. Based on adoptive cellular therapy's clinical success against childhood …

The clinical application of chimeric antigen receptor (CAR) T‐cell therapy has rapidly
changed the treatment options for terminally ill patients with defined blood‐borne cancer …

Pediatric brain tumors are the most common solid malignancies in children. Advances in the
treatment of pediatric brain tumors have come in the form of imaging, biopsy, surgical …

The limited efficacy of traditional cancer treatments, including chemotherapy, radiotherapy,
and surgery, emphasize the significance of employing innovative methods. CAR (Chimeric …

Pediatric brain and spinal cancers are collectively the leading disease-related cause of
death in children; thus, we urgently need curative therapeutic strategies for these tumors. To …

Glioblastoma (GBM) is the most common malignant primary brain cancer in adults. It is
always resistant to existing treatments, including surgical resection, postoperative …

Tumor immune microenvironment (TIME) consists of intra-tumor immunological components
and plays a significant role in tumor initiation, progression, metastasis, and response to …

Circular mRNA (cmRNA) is particular useful due to its high resistance to degradation by
exonucleases, resulting in greater stability and protein expression compared to linear …